Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Polio Vaccination Strategies Assessed as Eradication Nears

21.12.2005


Polio is on track to become only the second disease ever eradicated. In two studies in the Dec. 15 issue of The Journal of Infectious Diseases, now available online, scientists are working to ensure that once it is gone, it stays gone. One study reduces concerns that people whose immune systems were weakened by HIV would re-introduce poliovirus into the community. The other study looks at the how switching forms of vaccine from a live, attenuated vaccine to an inactivated version may affect communities.



Oral polio vaccine (OPV), one of the vaccines instrumental in driving the disease to near-eradication, contains weakened live virus strains. The vaccine is highly effective, easy to administer, relatively inexpensive, and has been used for more than 40 years. Those given the vaccine excrete, or “shed,” virus in their stool. There is some concern over the use of OPV, however, because vaccine-derived poliovirus (VDPV) can occasionally cause another form of polio.

Furthermore, in rare cases, immunodeficient persons have shown prolonged shedding of VDPV, which may be transmitted to contacts, thus potentially re-introducing polio into the community. Concerns had been raised that this issue would be a particular challenge in countries with high HIV prevalence.


Karen Hennessey, PhD, MSPH, and colleagues in Cote d’Ivoire and at the Centers for Disease Control and Prevention examined the duration of shedding of oral poliomyelitis vaccine by individuals with HIV infection.

Dr. Hennessey and colleagues tested stool specimens at various intervals following vaccination. Out of a total of 419 adults with HIV infection, no poliovirus was isolated from any of the specimens. Because of these results, it is likely that fewer than 1 percent of adults with HIV infection experience prolonged virus shedding when exposed to OPV, “and therefore probably represent minimal risk of re-introducing vaccine virus into the population after poliovirus has been eradicated,” the authors concluded.

The alternative to OPV, a live virus vaccine, is an inactivated polio vaccine (IPV). IPV is safer because the inactivated virus in IPV cannot mutate into paralytic VDPV. However, the immune response generated in the digestive tract by IPV was believed to be less potent that that of OPV. Therefore, although those immunized with IPV would be protected from polio, they could still be infected and shed virus, contributing to the spread of the disease.

But all research on the subject had been performed using only one dose of a vaccine that was less potent that the currently used version. Konstantin Chumakov, PhD, and colleagues at the Food and Drug Administration and various other institutions throughout the United States revisited the issue using two doses of the newer, enhanced vaccine.

They found that two doses of IPV did produce immunity in the digestive tract. The researchers used shedding of virus after treatment with a dose of OPV to measure the immune response. Seventy-five percent of children receiving two doses of IPV, followed by one dose of OPV, shed OPV virus a week later, compared to 92 percent of those receiving just one dose of OPV. After three weeks, 81 percent of the children receiving one OPV dose were still shedding virus, while only 37 percent of those immunized with IPV first were. The amount of virus shed was also lower in those receiving IPV.

However, the mucosal immunity generated by IPV was less than that achieved by OPV. After two doses of OPV, only 22 percent of children given a third dose of OPV were shedding virus after a week. That figure dropped to 5 percent after three weeks.

The researchers concluded that IPV-immunized communities are partially protected from spread of poliovirus. Better protection may be achieved by enhancing IPV further, they said.

However, an accompanying editorial by Harry F. Hull, MD, and Philip D. Minor, MD, at the Minnesota Department of Health and the U.K. National Institute for Biological Standards and Control noted that “the time and expense of developing, testing and securing regulatory approval for a new IPV makes it unlikely that such a vaccine could be available on a timely basis.” They also discussed public health, ethical, and financial reasons for stopping vaccination once poliovirus is effectively non-existent, and the risks associated with doing so. Whereas Hull and Minor blame politics and complacency as ultimately being the biggest threats to polio eradication, they conclude that choosing an appropriate vaccination strategy to prevent poliovirus re-introduction is an important and unavoidable task.

Steve Baragona | EurekAlert!
Further information:
http://www.idsociety.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

Quantum optical sensor for the first time tested in space – with a laser system from Berlin

23.01.2017 | Physics and Astronomy

The interactome of infected neural cells reveals new therapeutic targets for Zika

23.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>